The current analysis found MRI screening in the DENSE trial detected invasive breast cancers about 6 years earlier than mammography. The calculation is based on first and second round invasive cancer detection rates. The 6 years is also consistent with the trial’s high false positive rate in the second round that used “prior” first round exams to estimate lesion growth over the 2 years between rounds. The “how much earlier” measure provides an additional means for comparing the relative performance of breast cancer screening modalities.
This abstract and the presentation materials are available to members only; a login is required.